Fort Washington Investment Advisors Inc. OH Has $169.53 Million Stock Holdings in Becton, Dickinson and Company $BDX

Fort Washington Investment Advisors Inc. OH grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.0% in the third quarter, HoldingsChannel reports. The fund owned 905,757 shares of the medical instruments supplier’s stock after acquiring an additional 17,844 shares during the period. Becton, Dickinson and Company makes up 0.9% of Fort Washington Investment Advisors Inc. OH’s portfolio, making the stock its 23rd largest position. Fort Washington Investment Advisors Inc. OH’s holdings in Becton, Dickinson and Company were worth $169,531,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in BDX. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. Jump Financial LLC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $321,000. WPG Advisers LLC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $36,000. Vident Advisory LLC increased its position in shares of Becton, Dickinson and Company by 185.8% in the first quarter. Vident Advisory LLC now owns 11,082 shares of the medical instruments supplier’s stock valued at $2,539,000 after acquiring an additional 7,204 shares during the last quarter. Finally, Baird Financial Group Inc. raised its holdings in Becton, Dickinson and Company by 15.9% during the first quarter. Baird Financial Group Inc. now owns 103,729 shares of the medical instruments supplier’s stock worth $23,760,000 after acquiring an additional 14,266 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.7%

Shares of Becton, Dickinson and Company stock opened at $195.02 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The business has a fifty day simple moving average of $190.44 and a two-hundred day simple moving average of $186.52. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The company has a market capitalization of $55.56 billion, a price-to-earnings ratio of 33.45, a P/E/G ratio of 1.81 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 629 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the transaction, the executive vice president owned 13,105 shares of the company’s stock, valued at approximately $2,568,973.15. This represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 1,052 shares of company stock valued at $201,235. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BDX. Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Jefferies Financial Group increased their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Finally, Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday, November 7th. Four equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $205.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.